Gushengtang Holdings Ltd
Gushengtang Holdings Ltd operates in the pharmaceuticals segment of the healthcare industry, primarily generating revenue through the production and distribution of traditional Chinese medicine products.
Business. Gushengtang Holdings Ltd (2273.HK) is a healthcare company primarily engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not available.
Analyst recommendations
20 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Gushengtang Holdings Ltd (2273.HK) is a healthcare company primarily engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not available.
Gushengtang Holdings Ltd has a market capitalization of 6.02 billion CNY, with a current market price of 26.36 CNY per share. The company's shares are fully diluted, with no additional shares outstanding beyond the basic shares of 228.45 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and returns are not directly quantified in the available data, but its mean price target of 41.85 CNY and median price target of 39.00 CNY suggest a positive outlook from analysts. The high price target of 67.35 CNY and low price target of 27.84 CNY indicate a wide range of expectations, with a mean recommendation of 1.80, which is a strong buy signal.
Geographic and segment exposure is not explicitly detailed in the available data, but the company's primary business is in the production and distribution of traditional Chinese medicine products. This suggests a concentration in the domestic Chinese market, though international expansion is not ruled out.
The company's growth trajectory is supported by a strong analyst consensus, with 7 strong-buy and 12 buy recommendations, and no hold or sell ratings. This indicates a positive sentiment towards the company's future performance and potential for growth.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The dilution risk is currently low, with no additional shares outstanding beyond the basic shares. No specific dilution adjustments or sources are identified in the available data.
Recent events and filings do not provide specific details, but the strong analyst recommendations and wide range of price targets suggest that the company is under active scrutiny and has a positive outlook in the market.
- Gushengtang Holdings Ltd is a pharmaceutical company with a strong analyst consensus, indicating positive market sentiment.
- The company's market price is significantly below the mean and median price targets, suggesting potential for appreciation.
- The absence of liquidity risk assessment and balance-sheet data introduces uncertainty in the company's financial health.
- The company's business is concentrated in traditional Chinese medicine, with no detailed geographic or segment breakdown provided.
- Analysts have a strong buy bias, with no hold or sell ratings, indicating confidence in the company's future performance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥3.25B, +7,5% YoY; Operating income +18,3% YoY.
- ▍Revenue ¥3.25B, +7,5% YoY
- ▍Operating income +18,3% YoY
- ▍Net income +15,0% YoY
- ▍Free cash flow −24,0% YoY
- ▍Net margin 10.9%
Revenue ¥3.02B, +30,1% YoY; Operating income +23,2% YoY.
- ▍Revenue ¥3.02B, +30,1% YoY
- ▍Operating income +23,2% YoY
- ▍Net income +21,6% YoY
- ▍Free cash flow +65,0% YoY
- ▍Net margin 10.2%
Revenue ¥2.32B, +43,0% YoY; Operating income +43,5% YoY.
- ▍Revenue ¥2.32B, +43,0% YoY
- ▍Operating income +43,5% YoY
- ▍Net income +39,5% YoY
- ▍Free cash flow −18,3% YoY
- ▍Net margin 10.9%
Revenue ¥1.62B, +18,4% YoY; Operating income +144,0% YoY.
- ▍Revenue ¥1.62B, +18,4% YoY
- ▍Operating income +144,0% YoY
- ▍Net income +135,7% YoY
- ▍Free cash flow +154,0% YoY
- ▍Net margin 11.1%
Revenue ¥1.37B; Operating income -¥490.7M.
- ▍Revenue ¥1.37B
- ▍Operating income -¥490.7M
- ▍Net margin -37.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,90 |
| Revenue | —no estimate | —no estimate | 3,8B CNY |
| Operating income | —no estimate | —no estimate | 532,6M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Gushengtang Holdings Ltd Market data — financials · 2026-05-26
- Gushengtang Holdings Ltd Market data — analyst estimates · 2026-05-26